RAM
OTLK icon

Riggs Asset Management’s Outlook Therapeutics OTLK Stock Holding History

Riggs Asset Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,500
Closed -$4K – 629
2025
Q2 		$4K Hold
2,500
– – ﹤0.01% 507
2025
Q1 		$3.05K Hold
2,500
– – ﹤0.01% 368
2024
Q4 		$4.65K Buy
+2,500
New +$10.3K ﹤0.01% 305

Other funds holding OTLK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riggs Asset Management's OTLK Position: Q3 2025 in Review

Riggs Asset Management sold out of Outlook Therapeutics (OTLK) in Q3 2025, closing a stake of 2,500 shares — an estimated $4K sold.

Riggs Asset Management first reported a position in OTLK in Q4 2024 and held it in 3 quarters. The position peaked at $4.65K in Q4 2024. 54 funds tracked by Wall St. Rank hold OTLK as of Q3 2025.

  • Riggs Asset Management reported no remaining Outlook Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 2,500 Outlook Therapeutics shares in Q3 2025, an estimated $4K.
  • Riggs Asset Management first reported a position in Outlook Therapeutics in Q4 2024 and held it in 3 quarters.
  • Riggs Asset Management's Outlook Therapeutics position peaked at $4.65K in Q4 2024.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.